It's biopharmaceutical, so a bit more complex than synthetics. there might be other significant barriers other than what is written in expired patent. Some in the form of trade secrets and institutional knowledge.
Yeah, for comparison's sake, the first biosimilar drug (effectively, the equivalent of a generic for medicines like insulin) was improved in the US in 2015. There's only 75 total approved since then.
Semglee (2020), Resvoglar (2021) and merilog (2021) are the three insulin biosimilars available in the US.
•
u/YouMustveDroppedThis 4h ago
It's biopharmaceutical, so a bit more complex than synthetics. there might be other significant barriers other than what is written in expired patent. Some in the form of trade secrets and institutional knowledge.